Cancers, Vol. 15, Pages 4478: Evaluation of Temozolomide and Fingolimod Treatments in Glioblastoma Preclinical Models

Cancers, Vol. 15, Pages 4478: Evaluation of Temozolomide and Fingolimod Treatments in Glioblastoma Preclinical Models Cancers doi: 10.3390/cancers15184478 Authors: Mélodie Davy Laurie Genest Christophe Legrand Océane Pelouin Guillaume Froget Vincent Castagné Tristan Rupp Glioblastomas are malignant brain tumors which remain lethal due to their aggressive and invasive nature. The standard treatment combines surgical resection, radiotherapy, and chemotherapy using Temozolomide, albeit with a minor impact on patient prognosis (15 months median survival). New therapies evaluated in preclinical translational models are therefore still required to improve patient survival and quality of life. In this preclinical study, we evaluated the effect of Temozolomide in different models of glioblastoma. We also aimed to investigate the efficacy of Fingolimod, an immunomodulatory drug for multiple sclerosis also described as an inhibitor of the sphingosine-1-phosphate (S1P)/S1P receptor axis. The effects of Fingolimod and Temozolomide were analyzed with in vitro 2D and 3D cellular assay and in vivo models using mouse and human glioblastoma cells implanted in immunocompetent or immunodeficient mice, respectively. We demonstrated both in in vitro and in vivo models that Temozolomide has a varied effect depending on the tumor type (i.e., U87MG, U118MG, U138MG, and GL261), demonstrating sensitivity, acquired resistance, and purely resistant tumor phenotypes, as observed in...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research